Apax shareholding in Galapagos placed with institutional investors

Mechelen, Belgium; 17 June 2010 – Galapagos NV (Euronext: GLPG) announced that Kempen and Co. placed nearly 1.3 million Galapagos shares (5.4% of total outstanding shares) through an accelerated bookbuilding today.  These shares were held by Apax, who obtained their position in Galapagos through the venture capital financing round in 2002.  The shares were placed with European institutional investors.


“I am very pleased that there is so much institutional investor interest in Galapagos and that this placement could be executed in only a couple of hours.  We thank Apax for their support as a shareholder over the past eight years and welcome the new shareholders,” said Onno van de Stolpe, CEO of Galapagos.


About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing one of the largest pipelines in biotech, with four clinical and over 50 small molecule discovery/pre-clinical programs.  Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co. and Roche, Galapagos is eligible to receive up to €3 billion in downstream milestones, plus royalties.  Together with its BioFocus and Argenta service operations, Galapagos has over 670 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at: www.glpg.com





Galapagos NV

Onno van de Stolpe, CEO

Tel: +31 6 2909 8028



Elizabeth Goodwin, Director Investor Relations

Tel: +31 6 2291 6240




This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.